Amanda Marinoff

I am a pediatric oncologist and clinician-scientist with interests in developmental therapeutics, clinical trials, and translational genomics. My clinical and translational research focuses on advancing precision oncology in osteosarcoma.
Education
Fellowship, 2023 - Pediatric Hematology/Oncology, University of California San Francisco
Residency, 2020 - Pediatrics, Boston Children's Hospital and Boston Medical Center
MD, 2017 - Medicine, Harvard Medical School
BA, - , Dartmouth College
Honors and Awards
  • Advancing Precision Oncology in Osteosarcoma, NCI K12, 2024-2026

  1. Marinoff AE, Nathrath M, Shulman DS, Whittle SB, Pavisic J, Spentzos D, Albert CM, Nash JO, Shlien A, Cortés-Ciriano I, Marchais A, López-Fuentes E, Curtis C, Sweet-Cordero EA, Gorlick R, DelRocco N, Chugh R, Tap WD, Flanagan AM, Gaspar N, Crompton BD, Reed DR, Janeway KA, Grohar PJ, Livingston JA, Roberts RD. An international framework for clinical translation of molecular classifiers in osteosarcoma. NPJ precision oncology 2026. PMID: 42086782


  2. Marinoff AE, Thrall A, Aaronson K, Braun BS, Castellanos M, Chu J, Hermiston M, Huang BJ, Levinson A, Southworth E, Winger BA, Olshen A, Stieglitz E. Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies. Pediatric blood & cancer 2025. PMID: 39780402


  3. Young EP, Marinoff AE, Lopez-Fuentes E, Sweet-Cordero EA. Osteosarcoma through the Lens of Bone Development, Signaling, and Microenvironment. Cold Spring Harbor perspectives in medicine 2024. PMID: 38565264


  4. Shumock SS, Temple WC, Marinoff A, Aaronson K, Southworth E, Xirenayi S, Lee AG, Leung SG, Sweet-Cordero EA, Hermiston M, Higham C, Stieglitz E. Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients. Cancer reports (Hoboken, N.J.) 2023. PMID: 37933765


  5. Meyer LK, Huang I, Huang BJ, Chung JH, Pawar A, Hermiston ML, Loh ML, Ohgami RS, Ruiz-Cordero R, Bhargava P, Marinoff AE. Hemophagocytic lymphohistiocytosis and clonally related T-cell malignancies in a pediatric patient. Pediatric blood & cancer 2023. PMID: 37702960


  6. Marinoff AE, Aaronson K, Agrawal AK, Braun BS, Golden C, Huang BJ, Michlitsch J, Southworth E, Thrall A, Vo KT, Stieglitz E. Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies. Pediatric blood & cancer 2023. PMID: 37036306


  7. Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, Doan D, Corson L, Mauguen A, Pinto N, Maese L, Colace S, Macy ME, Kim A, Sabnis AJ, Applebaum MA, Laetsch TW, Glade-Bender J, Weiser DA, Anderson M, Crompton BD, Meyers P, Zehir A, MacConaill L, Lindeman N, Nowak JA, Ladanyi M, Church AJ, Cherniack AD, Shukla N, Janeway KA. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. Volume 7. JCO precision oncology 2023. PMID: 36996377


  8. Lu KL, Menke JR, Ng D, Ruiz-Cordero R, Marinoff A, Stieglitz E, Gollapudi S, Singh K, Ohgami RS, Vohra P. Cytomorphologic features of pediatric-type follicular lymphoma on fine needle aspiration biopsy: case series and a review of the literature. Journal of the American Society of Cytopathology 2022. PMID: 35843844


  9. Marinoff AE, Ma C, Guo D, Snuderl M, Wright KD, Manley PE, Al-Sayegh H, Sinai CE, Ullrich NJ, Marcus K, Haas-Kogan D, Goumnerova L, London WB, Kieran MW, Chi SN, Fangusaro J, Bandopadhayay P. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. Volume 135 of Issue 1. Journal of neuro-oncology 2017. PMID: 28733870